RavelcareShare price, financial results, shareholding and management
- Market cap
- ₹64 cr
- Stock P/E
- 12.4peers 44.2
- Book value
- ₹54.5
- Price to book
- 1.71
- EV / operating profit
- -
- Market cap to sales
- 2.37
- ROCE · FY26
- 29.6%
- ROE · FY26
- 21.6%
- ROE, 3-year average
- 91.5%
- Operating margin · FY26
- 26.2%peers 14.0%
- Sales growth, 3 years
- 97.8%
- Profit growth, 3 years
- 109.5%
- Debt to equity
- 0.00peers 0.26
- Borrowings
- ₹0 cr
- Interest cover
- No interest
- Cash from business / op. profit
- -247%
- Debtor days
- 96
- Pledged
- 0.00%
- Promoter holding
- 72.94%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 363
- 52-week high / low
- ₹215 / ₹81
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.
Ravelcare share price chart
Close on 6 Nov 2026 · +4.49% on the day · Vol 2,000
Daily prices to 6 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 6 Nov 2026
- 1 month
- -4.1%
- 3 months
- -21.5%
- 6 months
- -53.0%
- Traded a day, 20 days
- ₹0.03 cr
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +8% | +1% |
| 3 years, a year | +98% | +110% |
| Latest half, H2 FY26 | -14% | +30% |
Ravelcare revenue and profit growth
Half-yearly results · Profit and lossSales have grown very fast. Last year profit grew more slowly than sales, so the profit kept from each rupee of sales slipped.
SME companies report every six months. In the latest half, sales were lower than in the same half a year before. Profit grew faster than sales.
Ravelcare half-yearly results
SME companies report every six months · ₹ crore
| H2FY25 | H2FY26 | |
|---|---|---|
| Sales | 14.58 | 12.56 |
| Expenses | 13.30 | 9.83 |
| Operating profit | 1.28 | 2.73 |
| OPM | 8.8% | 21.7% |
| Interest | 0 | 0 |
| Depreciation | 0.05 | 0.03 |
| Profit before tax | 1.50 | 2.73 |
| Net profit | 1.50 | 1.95 |
Ravelcare profit and loss
Full years to March, FY22 to FY26 · ₹ crore, consolidated where reported
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Sales | 0.79 | 3.48 | 22.06 | 24.98 | 26.95 |
| Expenses | 1 | 2.97 | 15.35 | 18.16 | 19.89 |
| Operating profit | -0.21 | 0.51 | 6.71 | 6.82 | 7.06 |
| OPM | -26.6% | 14.7% | 30.4% | 27.3% | 26.2% |
| Other income | 0 | 0 | 0.19 | 0.32 | 0.08 |
| Interest | 0.01 | 0 | 0.07 | 0.01 | 0 |
| Depreciation | 0 | 0 | 0.02 | 0.10 | 0.07 |
| Profit before tax | -0.22 | 0.51 | 6.81 | 7.03 | 7.07 |
| Tax rate | 0.0% | -9.8% | 25.1% | 27.6% | 27.2% |
| Net profit | -0.23 | 0.56 | 5.10 | 5.09 | 5.15 |
| EPS ₹ | -460 | 1,120 | 10,200 | 10.17 | 9.20 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
A tax rate above 60% or below zero (FY23) comes from tax charged on a small or negative profit, as reported.
Earnings per share before FY24 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.
Ravelcare profitability
Margins and returns on capitalLast year the company kept about as much from each rupee of sales as the year before. It earns a high return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Operating margin | -26.6% | 14.7% | 30.4% | 27.3% | 26.2% |
| Tax rate | 0.0% | -9.8% | 25.1% | 27.6% | 27.2% |
| ROCE | · | 154.5% | 234.0% | 90.0% | 29.6% |
| ROE | · | · | 187.8% | 65.2% | 21.6% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ravelcare debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. It has almost no borrowings. Last year the business used more cash than it brought in. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Ravelcare balance sheet
At each 31 March · ₹ crore
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Equity capital | 0.01 | 0.01 | 0.01 | 5.01 | 6.86 |
| Reserves | -0.35 | 0.16 | 5.25 | 5.34 | 30.55 |
| Net worth | -0.34 | 0.17 | 5.26 | 10.35 | 37.41 |
| Borrowings | 0.42 | 0.41 | 0.04 | 0 | 0 |
| Other liabilities | -0.01 | 1.17 | 4.18 | 1.28 | 2.92 |
| Total liabilities | 0.07 | 1.75 | 9.48 | 11.63 | 40.33 |
| Fixed assets | 0 | 0.01 | 0.22 | 0.16 | 0.11 |
| Capital work in progress | 0 | 0 | 0 | 0 | 2.48 |
| Investments | 0 | 0 | 0.79 | 3.07 | 4.51 |
| Other assets | 0.07 | 1.74 | 8.47 | 8.40 | 33.23 |
Ravelcare cash flow
₹ crore
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Cash from operations | -0.41 | 1 | 6.49 | -3.18 | -17.47 |
| Cash from investing | 0 | -0.01 | -6.92 | 3.81 | -4.12 |
| Cash from financing | 0.41 | -0.01 | -0.44 | -0.04 | 21.91 |
| Net cash flow | 0 | 0.98 | -0.87 | 0.59 | 0.32 |
Working capital
Days
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Debtor days | 0 | 0 | 3 | 36 | 96 |
| Inventory days | 0 | 307 | 24 | 104 | 90 |
| Days payable | · | 149 | 73 | 21 | 72 |
| Cash conversion cycle | 0 | 158 | -46 | 119 | 115 |
| Working capital days | -166 | -87 | -32 | 50 | 119 |
Ravelcare peers and competitors
Listed SME companies in the same industryBy sales, Ravelcare is number 7 of the 8 listed SME companies in personal products.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Anondita Medicare | 1,903 | 56.0 | 137 | 34 | 37.0% | 0.26 |
| H. R. Hygiene Products | 139 | 12.6 | 130 | 11 | 14.0% | 0.51 |
| Recode Studios | 486 | 44.2 | 80 | 11 | 21.0% | 0.30 |
| Medistep Healthcare | 29 | 4.9 | 70.8 | 6 | 11.6% | 0.14 |
| Aakaar Medical Technologies | 101 | 15.1 | 67 | 6.6 | 15.4% | 0.34 |
| Macobs Technologies | 195 | 67.2 | 41.4 | 2.9 | 8.3% | 0.06 |
| Ravelcare | 64 | 12.4 | 27 | 5.2 | 26.2% | 0.00 |
| Novateor Research Laboratories | 23 | 227.0 | 3.8 | 0.1 | -2.6% | 0.09 |
| Median of the 7 others | 139 | 44.2 | 70.8 | 6.6 | 14.0% | 0.26 |
Ravelcare shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders has come down.
Ravelcare shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Dec 25 | Mar 26 | |
|---|---|---|
| Promoters | 72.94% | 72.94% |
| Foreign investors (FIIs) | 3.54% | - |
| Indian institutions (DIIs) | 8.14% | - |
| Number of shareholders | 470 | 363 |
Ravelcare latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹12.6 cr (-14%), net profit ₹2 cr (+30%) on H2 FY25.
- Shareholding, 31 March 2026: promoters unchanged at 72.94%.
Ravelcare announcements
4 on record, latest first; each opens the filing on the exchange
- Company UpdateCertificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2026PDF ↗
- Insider Trading / SASTIntimation of Trading Window ClosurePDF ↗
- AGM/EGMSubmission of Voting ResultsPDF ↗
- AGM/EGMProceedings of Annual General MeetingPDF ↗
Ravelcare annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Ravelcare share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Ravelcare's data · 7
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (68,59,000 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- !Earnings per share changes basis between FY24 (₹10,200.00) and FY25 (₹10.17) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
- ✓Revenue and profit are reported for every year shown, FY22 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Ravelcare
What does Ravelcare do?
Ravelcare is an SME company listed on BSE SME, in personal products.
What is the share price of Ravelcare?
₹93 at the close on 6 Nov 2026, from the exchange's daily figures.
What is the market cap of Ravelcare?
₹64 cr at the close on 6 Nov 2026, on 68,59,000 shares.
What is the P/E of Ravelcare?
12.4 times FY26 profit at the close on 6 Nov 2026 (our arithmetic).
What are Ravelcare's revenue and profit?
Revenue ₹27 cr and profit after tax ₹5 cr in FY26.
Who are the promoters of Ravelcare?
The promoter group; promoters held 72.94% at 31 March 2026.
What is Ravelcare's website?
www.ravelcare.com
More SME companies like Ravelcare
Other listed SME companies in personal products, the closest in size first, each read from its own documents.
- Aakaar Medical TechnologiesAAKAAR · NSE Emerge · Personal Products · listed 2025Market cap ₹103 cr
- H. R. Hygiene ProductsHRHYGIENE · BSE SME · Personal ProductsMarket cap ₹150 cr
- Medistep HealthcareMEDISTEP · NSE Emerge · Personal Products · listed 2025Market cap ₹26 cr
- Novateor Research LaboratoriesNOVATEOR · BSE SME · Personal ProductsMarket cap ₹24 cr
- Macobs TechnologiesMACOBSTECH · NSE Emerge · Personal Products · listed 2024Market cap ₹191 cr
- Recode StudiosRECODE · BSE SME · Personal ProductsMarket cap ₹434 cr
Built from 4 exchange announcements, 2 shareholding patterns and 5 years of reported results. Every figure carries its source; where the documents are silent, the page says so.